O ver the past 8 years several lines of compelling evidence have indicated that microRNAs are critical downstream effectors of classic oncogene/tumor suppressor networks. The archetypal examples of oncogene and tumor suppressor microRNAs are the miR-17-92 (oncomir 1) polycistron and miR-34 respectively. Whilst the involvement of these two opposing families of microRNAs in oncogenesis has been known for some time, the mRNA targets through which they exert their phenotypes are only just beginning to be uncovered. Moreover, several recent reports have demonstrated that the relevant physiological targets of certain individual microRNAs are actually fairly limited, with repression of just one or two major targets sufficient to explain the observed phenotype. In this review we will discuss the emerging role of microRNAs in tumorigenesis with a specific focus on miR-34c-dependent regulation of Myc.
Do MicroRNAs Act through the Many or the Few?
MicroRNAs are non-coding RNA molecules 18-24 nucleotides in length that regulate gene expression. They generally function by binding with imperfect Watson-Crick base pairing to target sequences within the 3' UTR of protein coding mRNAs leading to their translational repression. 1 There are over 700 identified microRNAs in the human genome which are, themselves, subject to regulation at the transcriptional and posttranscriptional levels. MicroRNAs are generally transcribed by RNA Polymerase
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A mechanism to prevent genomic instability? Ian G. Cannell 1 Once produced the primary microRNA (pri-miR) transcript is spliced and/or processed by the enzyme Drosha to form a precursor microRNA (pre-miR) which is exported from the nucleus and further processed by the RNAse III enzyme Dicer to form the mature microRNA duplex. 2 One strand of this duplex is loaded into one of the Argonaute protein family members (AGO1-4 in mammals) which recruits other factors such as GW182 (TNRC6A-C) to form a microRNAinduced silencing complex (miRISC). MiRISC is recruited to the 3' UTR 1 of mRNA targets by virtue of microRNA-mRNA base pairing, thus eliciting translational repression and/or mRNA destabilisation. The magnitude of translational repression appears to differ between microRNA-mRNA pairs for reasons that remain unknown, although there is evidence that sequence specific RNA binding proteins have a role to play. 3 Indeed, the precise mechanism by which microR-NAs repress the translation of their target mRNAs is a matter of debate with many factors being implicated in this process. 1 Each individual microRNA in the genome is predicted to regulate, on average, upwards of 200 protein coding mRNAs by binding to target sites within the 3' UTR. However, identifying the mRNAs that are true physiological targets of a given microRNA is a major challenge within the field. It has been proposed that microRNAs exert their function by acting as rheostats to fine-tune gene expression extra view extra view are numerous reports of alterations in miR-34 expression in cancer highlighting the importance of this microRNA family in oncogenesis. For example, miR-34a is deleted in ~30% of neuroblastomas and the miR-34b/c promoter region is frequently epigentically silenced in metastatic cancer cell lines. (For further examples of miR-34 alterations in cancer see Table 1 ). The different members of the miR-34 family target several cell cycle regulators although which of these mRNAs is/are responsible for their antiproliferative affects and whether the three members have distinct or overlapping targets is only starting to be elucidated. Furthermore, the precise role of miR-34 in the DNA damage response is yet to be fully defined.
We have recently shown that Myc is negatively regulated by miR-34c in response to DNA damage and that this is a crucial event in limiting Myc-induced DNA synthesis. Inhibition of miR-34c following DNA damage prevents S-phase arrest and leads to increased DNA synthesis, DNA damage and checkpoint activation. Remarkably, despite the number of predicted (and known) mRNA targets of miR-34c all these phenotypes of miR-34c inhibition are reversed when miR-34c is inhibited in combination with depletion of Myc by RNAi. 11 These data suggest that following DNA damage Myc is a major target of miR-34c and have important implications for our understanding of Myc biology. Continued replication under stress conditions may be one mechanism by which Myc promotes genomic instability and achieves its oncogenic potential. 32 Our data argue that miR-34c lies at the centre of a pathway that acts to remove Myc in order to prevent this oncogenic function ( Fig. 2) . Whilst Myc is clearly an important target of miR-34c we cannot rule out the possibility that other miR-34c targets are important in different cellular contexts. However, several other miR-34c targets, both experimentally validated and predicted, are also transcriptional targets of Myc (www.myc-cancer-gene.org) so these targets may be controlled by miR-34c both directly (by translational repression via their 3' UTR) and indirectly (by a reduction in transcription due a decrease in Myc levels). One target of miR-34c that cell cycle, primarily through the Mycassociated zinc finger protein, Miz1. 14, 15 In addition to regulating protein coding mRNAs, Myc transcriptionally regulates a number of non-coding RNA transcripts including ribosomal RNAs, tRNAs and microRNAs. 16 Myc has been a major focus of microRNA research for many years. It globally represses microRNA transcription, 17 inhibits the biogenesis of the tumor suppressor microRNA let-7 through Lin-28, 18 and specifically activates certain oncogenic microRNAs such as miR-17-92. 19, 20 MiR-17-92 is a polycistronic microRNA cluster consisting of miR-17, 18a, 19a, 20a, 19b and 92a that is transcriptionally activated by Myc, 19 co-operates with Myc to accelerate B-cell lymphomagenesis 20 and augments tumor angiogenesis. 21 Until recently it was unknown whether the oncogenicity of miR-17-92 was due to the concerted action of all its components or whether it could be attributed to a single microRNA. Two recent reports demonstrated that miR-19 is the principal oncogenic component of this cluster in vivo and suggest that the tumor suppressor PTEN is a major target of miR-19. [22] [23] [24] Myc also has non-transcriptional functions. It directly interacts with components of the replication machinery to positively regulate DNA synthesis. Overexpression of Myc in this context causes inappropriate replication origin firing leading to replication stress and genomic instability evidenced by the activation of a DNA damage response. 25 This is particularly important since genomic instability is a hallmark of cancer 26 and is evident in Myc-driven tumors in vivo. 27 Clearly these pleiotropic functions mean Myc must be tightly controlled in order to prevent tumorgenesis, although Myc alone cannot transform cells and requires at least one co-operating oncogene. 28 The miR-34 family comprising miR-34a, 34b and 34c, were first identified as direct transcriptional targets of p53. 12, [29] [30] [31] MiR-34a is the most well characterised family member and is transcribed from a separate locus to miR-34b/c which are produced as a single primary transcript. 13 All three of these microRNAs have potent anti-proliferative affects with miR-34a additionally promoting apoptosis. 13 There through modestly (10-20%) repressing a large number of mRNAs and this is supported by large scale proteomic studies. 4, 5 However, there is increasing evidence that the observed phenotype of certain microRNAs that act as master regulators of cell fate can be explained by the substantial repression (50-70%) of a fairly limited (2-3) repertoire of important mRNA targets. For example, miR-31 inhibits tumor metastasis, a phenotype that can be explained by repression of just three targets; RhoA, integrin-alpha5 and radixin. 6, 7 Similarly, the pro-metastatic microRNA miR-10b appears to function primarily by repressing HOXD10, since the phenotype of miR-10b inhibition is reversed when HOXD10 is depleted by RNAi. 8 Using "knock-in" technology two groups simultaneously demonstrated that expression of an activation induced cytidine-deaminase (AID) mRNA with a mutant miR-155 target-site in its 3' UTR partially phenocopies deletion of miR-155 in vivo. 9, 10 Taken together these observations suggest that certain microRNAs act on a subset of critical mRNA targets which are necessary and sufficient to explain the majority of their effects, although this does not rule out the possibility that the modest repression of a more substantial number of mRNAs contributes to both the magnitude and robustness of the phenotype. Our recent data suggest that Myc is a major physiological target of miR-34c in response to DNA damage-inducing chemotherapy, 11 providing mechanistic insight into the anti-proliferative effects of this tumor suppressor microRNA. 12, 13 
Myc is a Major Target of miR-34c in Response to DNA Damage
The proto-oncogene c-Myc (hereafter referred to as Myc) is a master regulator of cell proliferation and transformation through both transcriptional and nontranscriptional means and is frequently deregulated in human malignancies. As a transcription factor Myc binds to E-box elements (with its partner Max) and activates the transcription of genes whose products function to drive cell cycle progression and cell growth. Myc also negatively regulates the transcription of genes which function to arrest the MK2, evolved prior to the p53-dependent mechanism. Since p38 MAPK is a general stress-response kinase activated by a diverse range of stimuli, 40 it is possible that the p38 MAPK/MK2 acting through miR-34c may control Myc-dependent DNA synthesis in response to a variety of different stresses. Indeed induction of miR-34c and repression of Myc occur in response to sodium arsenite treatment ( Fig. 1) , a general p38 MAPK activator. 41 We propose that the p38 MAPK/MK2/ miR-34c pathway functions to prevent Myc-dependent DNA replication under stress. Loss of this regulatory mechanism may facilitate replication under stress and promote genomic instability, a potentially oncogenic function of Myc 32, 42, 43 (Fig. 2) .
Biological Significance of miR-34c-Mediated Repression of Myc
Members of the miR-34 family are known to induce a senescent-like growth arrest when overexpressed in cells, with miR-34c being the most potent. 12 We provided mechanistic insight into this striking effect by showing that miR-34c inhibition of Myc in response to DNA damage prevents S-phase progression. Thus miR-34c through repression of Myc cycle arrest thus allowing DNA repair. 34 Cancer cells frequently bypass one or more of these checkpoint pathways rendering such cells reliant upon the remaining checkpoints to maintain DNA damage below a threshold which induces cell death. In particular MK2 appears to be essential for S-phase and G 2 /M arrest in cells that are devoid of p53, and its inhibition specifically sensitises p53-deficient cells to DNA damage-induced cell death. 36 Therefore it would appear that checkpoint kinases and perhaps their downstream effectors may be attractive therapeutic candidates in specific cellular contexts. 37 The miR-34 family were first identified as direct transcriptional targets of p53, although induction of miR-34b/c in response to DNA damage 11 and miR-34a in response to B-Raf induced senescence 38 still occur in the absence of p53. We found that in the absence of p53 the p38 MAPK pathway, through MK2, controls miR-34b/c induction in response to DNA damage 11 raising the possibility that miR-34c may function as part of the MK2-mediated S-phase checkpoint. Indeed miR-34 induction in response to DNA damage in C. elegans is identical in wild-type and cep1/p53 mutant strains 39 suggesting that another mechanism, perhaps involving p38 MAPK/ cannot be ignored is Bcl-2, whilst neither Myc nor Bcl-2 on their own can convert cells to a tumorigenic state, together these potent oncogenes can co-operate to transform cells. 28, 33 The question of whether genetic loss of miR-34c alone leads to tumorgenesis in vivo, however, awaits the miR-34c "knock-out" mouse.
Pathways Upstream of miR-34c-Myc
Double-strand breaks to DNA caused by ionizing radiation or chemotherapeutic drugs initiate a DNA damage response. 34 The DDR links the recognition of DNA damage sites to cell cycle arrest (to allow DNA repair) or apoptosis (to eliminate the damaged cell) through a series of kinase signalling networks. 35 Doublestrand breaks are recognized by the MRN complex (consisting of Mre11, Rad50 and Nbs1) which, in conjunction with phosphorylated H2AX, amplifies the DNA damage signal. This in turn leads to local activation of the phosphotidyl inositol-3 kinase like (PI3K) family members ATM/ ATR, which transduce the signal to the downstream checkpoint kinases CHK1, CHK2 and p38 MAPK/MAPKAPK2. These checkpoint kinases, through phosphorylation of their substrates, initiate cell This idea is particularly pertinent in the context of pancreatic ductal adenocarcinoma (PDAC). In a mouse model of PDAC an initial activating mutation in KRAS is followed by senescence, however a second mutation in p53 (creating mutant p53(R175H)) bypasses this growth arrest and such cells progress to PDAC. 46 Mutation of p53 (R175H) leads to the expression of a stable protein with dominant-negative functions. 47 Since miR-34c is a p53 target gene it is tempting to speculate that mutant p53 may inhibit miR-34c induction, leading to upregulation of Myc and bypass of senescence. Interestingly, unlike complete loss of p53, mutant p53 (R175H) possess gain-of-function attributes including promotion of invasion and metastases. 48 Whilst hyper-methylation of the miR-34b/c promoter is well documented in metastatic cancer cells (see Table 1 , and references therein), this dominant negative function of mutant p53 in PDAC may be alternate mechanism to achieve suppression of miR-34b/c. Myc is known to be involved in metastasis 49 and has recently been shown to activate miR-9, a pro-metastatic microRNA, 50 therefore it is possible that miR-34c acts upstream of miR-9 by repressing Myc. In this view miR-34c would lie at the centre of a tumor suppressor network to prevent oncogenic transformation and metastasis by repressing Myc translation (Fig. 2) .
Future Directions
Several crucial questions remain regarding the regulation of Myc by miR-34c. Does miR-34c inhibit tumor metastasis by repressing Myc? Does genetic loss of miR-34c in vivo lead to tumor formation and is this dependent on Myc? Are there instances in human cancer in which this regulatory mechanism is lost, either through expression of mutant p53 or through a single nucleotide polymorphism (SNP) in the Myc 3' UTR? What function does miR-34c play in the MK2 DNA damage checkpoint? What transcription factor activates miR-34c in the absence of p53? Is therapeutic manipulation of miR-34c feasible? It is possible since therapeutic replacement of miR-34a in a mouse NSCLC xenograft model looks promising 61 and miR-34c is a more potent for example, requires continued high levels of Myc in order to bypass senescence and transform cells. 45 Under conditions in which miR-34c induction is intact activation of the DDR by Ras would repress Myc and induce senescence, however loss of this regulatory mechanism could lead to a bypass of this growth arrest, continued proliferation and genomic instability.
prevents continued DNA synthesis and proliferation in the presence of damaged DNA. 11 These data have important implications, since activated oncogenes can promote genomic instability and engage a DNA damage response (DDR) leading to oncogene-induced senescence, a permanent growth arrest and innate tumor suppressor mechanism. 44 Oncogenic Ras, anti-proliferative signal than miR34a. 12 Despite these many unanswered questions the available data clearly indicate a central role for miR-34c-dependent regulation of Myc in the prevention of human cancer initiation and progression.
